uniQure NV
Cerrado
44.69 -1.74
Resumen
Variación precio
24h
Mínimo
44.18
Máximo
45.72
Ingresos | -28M -81M |
|---|---|
Ventas | 2.3M 5.8M |
BPA | -1.22 |
Margen de beneficios | -1,387.759 |
Empleados | 221 |
EBITDA | -34M -70M |
Próximas Ganancias | 9 nov 2026 |
|---|
Capitalización Mercado | 460M 3.1B |
|---|---|
Apertura anterior | 46.43 |
Cierre anterior | 44.69 |
uniQure NV Gráfico
Resultados pasados no son un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
uniQure NV previsión
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de uniQure NV
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.